Pandect Bioventures
Pandect Bioventures is an early-stage life sciences investment firm that provides seed through Series A and later funding to biotech and pharmaceutical startups. The firm offers full management support, access to an onsite 40,000+ sq ft chemistry/biology incubator in South San Francisco, technical and financial research support, and advisory resources through executives-in-residence and academic/industry collaborators to advance discoveries toward patients.
Pandect Bioventures
Services
Equity investments (Seed, Series A and later rounds)
Direct funding including seed, Series A and participation in later rounds; co-investment and syndication with other venture funds.
Incubator space and onsite research facilities
Access to a 40,000+ square foot chemistry/biology incubator in South San Francisco with state-of-the-art research facilities and equipment.
Onsite CRO services and technical support
Contract research organization-style services and technical advisory staff to support research projects executed at the incubator.
Strategic guidance and advisory network
Access to executives-in-residence, top academic and industry advisors, and strategic business guidance from the management team.
In-licensing, NewCo spinout and partnership facilitation
Support for in-licensing of assets and formation of NewCos derived from later-stage research projects; collaborations with academic institutions and strategic partners.
Financial and technical project support
Direct financial support for research projects and technical assistance through the firm's network and incubator resources.
Equity investments (Seed, Series A and later rounds)
Direct funding including seed, Series A and participation in later rounds; co-investment and syndication with other venture funds.
Incubator space and onsite research facilities
Access to a 40,000+ square foot chemistry/biology incubator in South San Francisco with state-of-the-art research facilities and equipment.
Onsite CRO services and technical support
Contract research organization-style services and technical advisory staff to support research projects executed at the incubator.
Strategic guidance and advisory network
Access to executives-in-residence, top academic and industry advisors, and strategic business guidance from the management team.
In-licensing, NewCo spinout and partnership facilitation
Support for in-licensing of assets and formation of NewCos derived from later-stage research projects; collaborations with academic institutions and strategic partners.
Financial and technical project support
Direct financial support for research projects and technical assistance through the firm's network and incubator resources.
Portfolio
Co-invested in Series B with The Column Group and Nextech Invest; Chair of SAB is Nobel laureate William G. Kaelin Jr.
#Oncology (macrocyclic peptide discovery)
Formed as an oncology newco at the ShangPharma incubator with a UCSF co-founder; mission to deliver DDR-based oncology therapies.
#Oncology (DNA Damage Response)
Biotech spin-out from UC Berkeley; develops methods to modify therapeutic proteins to control pharmacokinetics and specificity.
#Ophthalmology (protein therapeutics)
Co-invested with The Emerson Collective; focuses on engineered B cell therapies for oncology, rare disease, regenerative medicine and autoimmune disease.
#Oncology (B cell medicines, cell-based therapeutics)
Co-invested with Arch Venture Partners; applies systems-based approaches to study and develop medicines directed to the kidney.
#Nephrology (kidney disease therapeutics)
Co-invested in Series B with The Column Group and Nextech Invest; Chair of SAB is Nobel laureate William G. Kaelin Jr.
#Oncology (macrocyclic peptide discovery)
Formed as an oncology newco at the ShangPharma incubator with a UCSF co-founder; mission to deliver DDR-based oncology therapies.
#Oncology (DNA Damage Response)
Biotech spin-out from UC Berkeley; develops methods to modify therapeutic proteins to control pharmacokinetics and specificity.
#Ophthalmology (protein therapeutics)
Co-invested with The Emerson Collective; focuses on engineered B cell therapies for oncology, rare disease, regenerative medicine and autoimmune disease.
#Oncology (B cell medicines, cell-based therapeutics)
Co-invested with Arch Venture Partners; applies systems-based approaches to study and develop medicines directed to the kidney.
#Nephrology (kidney disease therapeutics)